The overexpression of human epidermal growth factor receptor 2 (HER2) or the amplification of HER2 gene accounts for 15–20% of breast cancer, which is associated with biologically aggressive disease and reduced overall survival (OS) before the introduction of HER2-targeted therapies [1]. This evidence concerns the gene ERBB2 and breast carcinoma.